Edwards Lifesciences Corp (EW) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Edwards Lifesciences Corp's filing signal turned negative.

Edwards Lifesciences Corporation is a global leader in structural heart disease innovation, dedicated to improving patient lives through advanced technologies. The company focuses on transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical structural heart solutions. Its flagship SAPIEN family of valves is a leading TAVR therapy, supported by extensive clinical data and expanded indications. Edwards also offers differentiated TMTT solutions like the PASCAL and EVOQUE systems, and its surgical valves, featuring RESILIA tissue technology, are recognized for durability. The company operates worldwide, with significant sales in the United States, Europe, Japan, and Rest of World, and is committed to transformative product innovation and robust clinical evidence.

Revenue is primarily driven by sales of Transcatheter Aortic Valve Replacement (TAVR) products, which represented 74% of net sales in 2025. Sales of Transcatheter Mitral and Tricuspid Therapies (TMTT) and Surgical Structural Heart products also contribute to revenue.